Schonfeld Strategic Advisors LLC Acquires 3,372 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Schonfeld Strategic Advisors LLC lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 128.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,000 shares of the medical equipment provider's stock after acquiring an additional 3,372 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Lantheus were worth $537,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in LNTH. T. Rowe Price Investment Management Inc. raised its position in shares of Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after buying an additional 435,445 shares during the last quarter. Reinhart Partners LLC. lifted its stake in Lantheus by 9.9% in the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock worth $122,280,000 after purchasing an additional 123,282 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Lantheus by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock valued at $120,510,000 after purchasing an additional 30,891 shares during the last quarter. Swedbank AB grew its position in shares of Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after purchasing an additional 385,000 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Lantheus by 11.7% in the fourth quarter. Northern Trust Corp now owns 916,384 shares of the medical equipment provider's stock worth $81,980,000 after buying an additional 96,275 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Stock Performance

LNTH opened at $81.86 on Friday. The stock's 50 day moving average price is $99.57 and its 200-day moving average price is $94.25. Lantheus Holdings, Inc. has a one year low of $75.00 and a one year high of $126.89. The stock has a market cap of $5.61 billion, a price-to-earnings ratio of 13.62 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The business had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm's revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter last year, the business posted $1.69 earnings per share. As a group, analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 63,109 shares of company stock valued at $6,016,046. 2.00% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on LNTH shares. StockNews.com raised Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday. JMP Securities restated a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial lowered their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday. Finally, B. Riley reduced their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $132.67.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.